The biotechnology and early clinical research platforms of CIC-BT1431 and the CGFL
The interactions between the research teams of UMR866/UMR1098 and the medical oncology departments of Besançon University Hospital and the anti-cancer center in Dijon (CGFL) have led to the creation of biotechnology platforms for translational research.
-
A platform for preclinical evaluation and the development of immunological biotherapies (ITAC): the aim of the ITAC platform is to produce antibodies or vaccines and to develop biomarkers. The ITAC platform carries out preclinical evaluations of immunological biotherapies in vitro and in murine models for academic or industrial partners. The constitution of cohorts of patients (cancers of the colon, pancreas, breast and lung) and of exhaustive biological collections (plasma, peripheral blood, tumor-infiltrating lymphocytes) is a major plus for the evaluation of biotherapies in the precise context of the studied cancers.
- Platform to monitor immunology and pharmaco-immunology: the biomonitoring platform of our institutes will make it possible to follow immune and inflammatory responses associated with cancers in numerous interregional studies. The platform is certified ISO9001 and interacts with GERCOR (35 studies and 17000 technical samples in 2015).
- The early clinical research platform (CLIPP) to carry out phase I/II studies. Coordinated by Dr. Nicolas Isambert, the CLIPP platform, accredited by the Institut National de Cancer, carries out phase 0 and I studies for academic or industrial partners. Our teams also have an early clinical research activity based on the development of our own innovations. We thus analyze the interest of the neutralization of interleukin 1 in association with chemotherapy and anti-VEGFA (Ghiringhelli F et al). Phase I studies are also devoted to the evaluation of cytotoxic cell therapy (Borg C) and vaccination to induce CD4 TH1 T responses targeting telomerase (Adotevi O).
Website
